{
    "paper_id": "PMC7095324",
    "metadata": {
        "title": "SARS vaccines speed towards clinic",
        "authors": [
            {
                "first": "Helen",
                "middle": [],
                "last": "Pearson",
                "suffix": "",
                "email": null,
                "affiliation": {}
            }
        ]
    },
    "body_text": [
        {
            "text": "\n\n",
            "cite_spans": [],
            "section": "",
            "ref_spans": []
        },
        {
            "text": "US clinical trials of experimental SARS vaccines could begin within a year. But researchers are warning against rushing into human tests.",
            "cite_spans": [],
            "section": "",
            "ref_spans": []
        },
        {
            "text": "Teams around the world are racing to develop a vaccine to fight severe acute respiratory syndrome, in case the disease resurfaces. Many groups are already assessing their experimental vaccines in animals.",
            "cite_spans": [],
            "section": "",
            "ref_spans": []
        },
        {
            "text": "Results of one of the first such trials is published today. A team led by Andrea Gambotto of the University of Pittsburgh School of Medicine, Pennsylvania, has shown that six rhesus macaque monkeys injected with a SARS vaccine pumped out antibodies and immune cells that fight the coronavirus responsible for the disease.1",
            "cite_spans": [
                {
                    "start": 321,
                    "end": 322,
                    "mention": "1",
                    "ref_id": "BIBREF0"
                }
            ],
            "section": "",
            "ref_spans": []
        },
        {
            "text": "At least three other groups are thought to have already taken the next key step: showing that their vaccines actually protect animals such as monkeys or ferrets against SARS infection.",
            "cite_spans": [],
            "section": "",
            "ref_spans": []
        },
        {
            "text": "And Chinese government officials announced in late November that they were ready to begin human trials of a SARS vaccine made by Beijing-based company Sinovac Biotech.",
            "cite_spans": [],
            "section": "",
            "ref_spans": []
        },
        {
            "text": "But SARS vaccines, like those against some related animal coronaviruses, could actually worsen the infection. \"It's important that we don't rush in,\" says Gary Nabel, who heads the vaccine-research centre at the National Institutes of Health in Bethesda, Maryland. ",
            "cite_spans": [],
            "section": "",
            "ref_spans": []
        },
        {
            "text": "\n Fuel or fight\n",
            "cite_spans": [],
            "section": "",
            "ref_spans": []
        },
        {
            "text": " Vaccines trigger the production of antibodies that latch onto viruses. Vaccines also prompt white blood cells called macrophages to eat and destroy the antibody-tagged viruses. But in some cases, coronaviruses replicate inside the macrophages themselves ? fuelling, rather than fighting, the infection. This phenomenon is called antibody-mediated enhancement. ",
            "cite_spans": [],
            "section": "",
            "ref_spans": []
        },
        {
            "text": "So far, there is no sign that the SARS coronavirus reproduces in macrophages, says Chris Olsen, who studies animal vaccines at the University of Wisconsin-Madison. \"But it's important to document,\" he says.",
            "cite_spans": [],
            "section": "",
            "ref_spans": []
        },
        {
            "text": "It's happening at an unprecedented rate Gary Nabel , NIH",
            "cite_spans": [],
            "section": "",
            "ref_spans": []
        },
        {
            "text": "To check whether antibody-mediated enhancement will be a problem for SARS jabs, Nabel advises researchers to stick to small clinical trials at first. \"None of us wants to see a vaccine go forward that has any hint of doing harm,\" he says. ",
            "cite_spans": [],
            "section": "",
            "ref_spans": []
        },
        {
            "text": "\n Alternative therapy\n",
            "cite_spans": [],
            "section": "",
            "ref_spans": []
        },
        {
            "text": " There are many different routes to a SARS vaccine. Gambotto's team packaged three SARS genes, including one that helps the virus breach human cells, into a harmless virus. Once in the body, the virus makes proteins that trigger an immune response. ",
            "cite_spans": [],
            "section": "",
            "ref_spans": []
        },
        {
            "text": "The Sinovac Biotech vaccine takes a different approach: using a whole, dead strain of the SARS coronavirus. Other groups are using naked SARS DNA.",
            "cite_spans": [],
            "section": "",
            "ref_spans": []
        },
        {
            "text": "For now, it is unclear whether one or a combination of these tactics will ultimately prove most effective. Nabel predicts that as many as five candidate vaccines could be in small-scale clinical trials within a year. \"It's happening at an unprecedented rate,\" he says.",
            "cite_spans": [],
            "section": "",
            "ref_spans": []
        }
    ],
    "ref_entries": {},
    "back_matter": [],
    "bib_entries": {
        "BIBREF0": {
            "title": "Effects of a SARS associated coronavirus vaccine in monkeys",
            "authors": [
                {
                    "first": "W",
                    "middle": [],
                    "last": "Gao",
                    "suffix": ""
                }
            ],
            "year": 2003,
            "venue": "The Lancet",
            "volume": "362,",
            "issn": "",
            "pages": "1895 - 1896",
            "other_ids": {
                "DOI": [
                    "10.1016/S0140-6736(03)14962-8"
                ]
            }
        }
    }
}